You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Targets of Antibody-Drug Conjugates in NSCLC: Diagnostics, Emerging Therapies, and Future Prospects

  • Authors: Enriqueta Felip, MD, PhD; Michael Thomas, MD; Egbert Smit, MD
  • CME Released: 9/30/2022
  • Valid for credit through: 9/30/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for a global audience of oncologists, pulmonologists, and pathologists based outside of the United States.

The goal of this activity is that learners will be better able to understand the latest developments for ADCs in the treatment of NSCLC.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Different antigenic targets for ADCs in NSCLC
    • Latest clinical trial data for ADCs in NSCLC
  • Have greater competence related to
    • Managing adverse events of ADCs
  • Demonstrate greater confidence in their
    • Understanding of the implications of the latest clinical trial data for ADCs in NSCLC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Faculty

  • Enriqueta Felip, MD, PhD

    Medical Oncologist
    Head, Thoracic Malignancies
    Vall d'Hebron University Hospital
    Barcelona, Spain

     

    Disclosures

    Enriqueta Felip, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Amgen; AstraZeneca; Bayer; Bristol Myers Squibb; Daichii Sankyo; Eli Lilly and Company; F. Hoffmann La Roche; GlaxoSmithKline; Janssen; Merck; Merck Sharp & Dohme Corp; Novartis; Peptomyc; Pfizer; Sanofi; Takeda
    Speaker or member of speakers bureau for: AstraZeneca; Bristol Myers Squibb; Eli Lilly and Company; F. Hoffmann La Roche; Janssen; Medical Trends; Merck; Merck Sharp & Dohme; PeerVoice; Pfizer; Sanofi; Takeda; TouchOncology
    Research funding from: Merck HealthCare KGaA
    Other: Independent member of the board for: Grifols 

  • Michael Thomas, MD

    Professor of Medicine
    Head, Thoracic Oncology
    Thoraxklinik-Heidelberg
    Heidelberg University
    Heidelberg, Germany

     

    Disclosures

    Michael Thomas, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Celgene; Chugai; Daichii Sankyo; Eli Lilly and Company; GlaxoSmithKline; Janssen; Merck; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi; Takeda
    Speaker or member of speakers bureau for: Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; Janssen; Merck; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi; Takeda
    Research funding from: AstraZeneca; Bristol Myers Squibb; Roche; Takeda
    Contracted researcher for: Amgen; AstraZeneca 

  • Egbert Smit, MD

    Professor of Pulmonology
    Leiden University Medical Center
    Leiden, the Netherlands

     

    Disclosures

    Egbert Smit, MD, has the following relevant financial relationships: Consultant or advisor for: AstraZeneca; Bayer; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eli Lilly; Merck; Merck Sharp & Dohme; Novartis; Pfizer; Regeneron Pharmaceuticals; Sanofi; Takeda
    Speaker or member of speakers bureau for: AstraZeneca; Boehringer Ingelheim; Merck
    Research funding from: AstraZeneca; Bristol Myers Squibb; Merck; Merck Sharp & Dohme; Roche Genentech
    Contracted researcher for: Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Cullinan Oncology; Daiichi Sankyo, Inc.; Eli Lilly; Novartis; PharmaMar; Roche; Takeda

Editor

  • Megan Cannon, PhD

    Medical Education Director, WebMD Global, LLC

     

    Disclosures

    Megan Cannon, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Targets of Antibody-Drug Conjugates in NSCLC: Diagnostics, Emerging Therapies, and Future Prospects

Authors: Enriqueta Felip, MD, PhD; Michael Thomas, MD; Egbert Smit, MDFaculty and Disclosures

CME Released: 9/30/2022

Valid for credit through: 9/30/2023

processing....

Transcription en français

Download the pdf.

 

« Return to: Targets of Antibody-Drug Conjugates in NSCLC: Diagnostics, Emerging Therapies, and Future Prospects